AR054964A1 - Un compuesto que comprende derivados de fosforamida, procedimiento para preparar dicho compuesto y sus usos - Google Patents
Un compuesto que comprende derivados de fosforamida, procedimiento para preparar dicho compuesto y sus usosInfo
- Publication number
- AR054964A1 AR054964A1 ARP030104790A ARP030104790A AR054964A1 AR 054964 A1 AR054964 A1 AR 054964A1 AR P030104790 A ARP030104790 A AR P030104790A AR P030104790 A ARP030104790 A AR P030104790A AR 054964 A1 AR054964 A1 AR 054964A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituents
- alkoxy
- phenyl
- optionally substituted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 150000008039 phosphoramides Chemical class 0.000 title 1
- 125000001424 substituent group Chemical group 0.000 abstract 9
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical group 0.000 abstract 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 5
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- -1 nitro, carboxy Chemical group 0.000 abstract 3
- 125000004043 oxo group Chemical group O=* 0.000 abstract 3
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 abstract 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000003282 alkyl amino group Chemical group 0.000 abstract 2
- 125000004414 alkyl thio group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 2
- 125000004993 haloalkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 abstract 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- DMSZORWOGDLWGN-UHFFFAOYSA-N ctk1a3526 Chemical compound NP(N)(N)=O DMSZORWOGDLWGN-UHFFFAOYSA-N 0.000 abstract 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2433—Compounds containing the structure N-P(=X)n-X-acyl, N-P(=X)n-X-heteroatom, N-P(=X)n-X-CN (X = O, S, Se; n = 0, 1)
- C07F9/2437—Compounds containing the structure N-P(=X)n-S-(S)x-(X = O, S, Se; n=0,1; x>=1)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2433—Compounds containing the structure N-P(=X)n-X-acyl, N-P(=X)n-X-heteroatom, N-P(=X)n-X-CN (X = O, S, Se; n = 0, 1)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/653—Five-membered rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
Abstract
Reivindicacion 1: Un compuesto que comprende derivados ix fosforamida caracterizado por la formula general 1: donde: cada R1 representa independientemente hidrogeno, C1-6 alquilo, C1-6 haloalquilo, fenilo, heteroarilo o fenil C1-3 alquilo, donde todos los anillos de fenilo y heteroarilo pueden estar opcionalmente sustituidos por uno o más grupos halogeno, C1-4 alquilo o C1-4 alcoxi, o bien los dos sustituyentes R1 pueden estar unidos completando un anillo de 5 o 6 miembros saturado o parcialmente insaturado, que puede estar opcionalmente fusionado a un anillo de benceno; A representa un anillo de 5 o 6 miembros insaturado o parcialmente insaturado que puede contener opcionalmente de 1 a 3 heteroátomos seleccionados de entre N, O y S, donde los dos sustituyentes L y D están situados sobre átomos adyacentes del anillo A, y donde A puede estar además opcionalmente sustituido por uno o más sustituyentes R2; L representa un enlace sencillo, -O-, -S- o -NR3-; B representa C1-6 alquilo o bien un anillo seleccionado de entre fenilo, heteroarilo y C3-7 cicloalquilo, donde dichos anillos pueden estar opcionalmente sustituidos por uno o más sustituyentes R4; D representa fenilo o piridina opcionalmente sustituidos por uno o más halogenos; los grupos A y -SO2NHP(O)(OR1)2 se hallan situados sobre el anillo D en disposicion para el uno respecto al otro; cada R2 representa independientemente halogeno, ciano, nitro, carboxi, C1-4 alquilo, C2-4 alquenilo, C2-4 alquinilo, C1- 4 haloalquilo, hidroxi, C1-4 hidroxialquilo, C1-4 alcoxi, C1-4 haloalcoxi, C1-4 alquiltio, amino, C1-4 alquilamino, C1-4 dialquilamino, formilo, C1-4 alquilcarbonilo, C1-4 alcoxicarbonilo, C1-4 haloalcoxicarbonilo, C1-4 alcoxi-C1-3 alquilo, C1-4 alquilcarboniloxi-C1-3 alquilo, C3-7 cicloalquil-C1-4 alcoxi-C1-3 alquilo o C3-7 cicloalcoxi-C1-3 alquilo, o bien 2 sustituyentes R2 sobre el mismo átomo de carbono pueden formar juntos un grupo oxo; R3 representa hidrogeno o C1-4 alquilo; cada R4 representa independientemente halogeno, ciano, nitro, carboxi, C1-4 alquilo, C1-4 haloalquilo, hidroxi, C1-4 hidroxialquilo, C1-4 alcoxi, C1-4 haloalcoxi, C1-4 alquiltio, amino, C1-4 alquilamino, C1-4 dialquilamino, formilo, C1-4 alquilcarbonilo, C1- 4 alcoxicarbonilo o C1-4 haloalcoxicarbonilo, o bien 2 sustituyentes R4 sobre el mismo átomo de carbono pueden formar juntos un grupo oxo, y adicionalmente uno de los sustituyentes R4 puede representar un anillo de 5 o 6 miembros, saturado, insaturado o parcialmente insaturado que puede contener opcionalmente de 1 a 3 heteroátomos seleccionados de entre N, O y S y que puede estar opcionalmente sustituido por uno o más sustituyentes R5; cada R5 representa independientemente halogeno, hidroxi, nitro, ciano, amino, C1-4 alquilo, C1-4 haloalquilo, C1-4 alcoxi o C1-4 alquilcarbonilo, o bien 2 sustituyentes R5 sobre el mismo átomo de carbono pueden formar juntos un grupo oxo; y heteroarilo en las definiciones anteriores representa piridina, pirazina, pirimidina o piridazina; y sus sales y solvatos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200202992A ES2215474B1 (es) | 2002-12-24 | 2002-12-24 | Nuevos derivados de fosforamida. |
Publications (1)
Publication Number | Publication Date |
---|---|
AR054964A1 true AR054964A1 (es) | 2007-08-01 |
Family
ID=32669110
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030104790A AR054964A1 (es) | 2002-12-24 | 2003-12-22 | Un compuesto que comprende derivados de fosforamida, procedimiento para preparar dicho compuesto y sus usos |
Country Status (16)
Country | Link |
---|---|
US (1) | US7550497B2 (es) |
EP (1) | EP1583767B1 (es) |
JP (1) | JP4406371B2 (es) |
KR (1) | KR20050088144A (es) |
AR (1) | AR054964A1 (es) |
AT (1) | ATE473231T1 (es) |
AU (1) | AU2003302287A1 (es) |
BR (1) | BR0317719A (es) |
CA (1) | CA2511596A1 (es) |
CL (1) | CL2003002749A1 (es) |
DE (1) | DE60333312D1 (es) |
ES (1) | ES2215474B1 (es) |
HK (1) | HK1082508A1 (es) |
MX (1) | MXPA05006957A (es) |
NO (1) | NO20052994L (es) |
WO (1) | WO2004058778A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0500730A2 (en) * | 2005-07-29 | 2007-02-28 | Richter Gedeon Vegyuszeti Gyar | 1,2-diaryl-heterocyclic compounds, their preparation, pharmaceutical compositions comprising thereof and their use |
US8093246B2 (en) * | 2006-12-14 | 2012-01-10 | Lexicon Pharmaceuticals, Inc. | O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer |
CN102464652B (zh) | 2010-11-02 | 2013-08-28 | 北京欧博方医药科技有限公司 | 咪唑衍生物、制备方法及用途 |
KR101178947B1 (ko) * | 2011-04-29 | 2012-09-03 | 한국생명공학연구원 | 올레아놀린산 아세테이트를 유효성분으로 포함하는 tlr 및 il-6 매개성 질환 예방 또는 치료용 약학적 조성물 |
BR112014030629B1 (pt) | 2012-06-11 | 2021-12-21 | Bristol-Myers Squibb Company | Prófármacos de ácido fosforamídico de 5-[5-fenil-4-(piridin-2-ilmetilamino) quinazolin -2-il] piridina-3-sulfonamida e composição farmacêutica que os compreende |
WO2017127417A1 (en) * | 2016-01-19 | 2017-07-27 | Prospero Pharmaceuticals Llc | Phosphopantothenate compounds |
UA128288C2 (uk) | 2018-03-08 | 2024-05-29 | Інсайт Корпорейшн | СПОЛУКИ АМІНОПІРАЗИНДІОЛУ ЯК ІНГІБІТОРИ PI3K-<font face="Symbol">g</font> |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0503838A3 (en) * | 1991-03-08 | 1992-10-07 | Merck & Co. Inc. | Heterocyclic compounds bearing acidic functional groups as angiotensin ii antagonists |
JP3290657B2 (ja) * | 1991-05-01 | 2002-06-10 | メルク エンド カムパニー インコーポレーテッド | アンギオテンシンii拮抗剤として活性な酸性アラルキルトリアゾール誘導体 |
US5162340A (en) * | 1991-05-10 | 1992-11-10 | Merck & Co., Inc. | Substituted 1-(2h)-isoquinolinones bearing acidic functional groups as angiotensin ii antagonists |
US5474995A (en) * | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
DK0924201T3 (da) | 1993-11-30 | 2002-05-21 | Searle & Co | Tricyclisk substitueret pyrazolylbenzensulfonamider og deres anvendelse som cyclooxygenase II-inhibitorer |
JP2636819B2 (ja) | 1994-12-20 | 1997-07-30 | 日本たばこ産業株式会社 | オキサゾール系複素環式芳香族化合物 |
CN1107058C (zh) | 1995-02-13 | 2003-04-30 | G·D·瑟尔公司 | 用于治疗类症的取代的异噁唑 |
CA2221692A1 (en) * | 1995-05-19 | 1996-11-21 | G.D. Searle & Co. | Substituted oxazoles for the treatment of inflammation |
ES2125161B1 (es) | 1996-03-21 | 1999-11-16 | Grupo Farmaceutico Almirall S | Nuevos derivados de 2-(3h)-oxazolona. |
PL195955B1 (pl) * | 1996-04-12 | 2007-11-30 | Searle & Co | Związek, pochodna benzenosulfonamidu, sposób jegowytwarzania, kompozycja farmaceutyczna zawierająca go oraz jego zastosowanie |
TNSN99111A1 (fr) | 1998-06-11 | 2005-11-10 | Pfizer | Derives de sulfonylbenzene nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant. |
AR024222A1 (es) * | 1998-10-16 | 2002-09-25 | Palau Pharma Sa | Imidazoles con actividad antiinflamatoria un procedimiento para su preparacion y composiciones farmaceuticas que lo contienen |
ES2166710B1 (es) | 2000-04-25 | 2004-10-16 | J. URIACH & CIA, S.A. | Nuevos compuestos heterociclicos con actividad antiinflamatoria. |
US20030105144A1 (en) | 2001-04-17 | 2003-06-05 | Ping Gao | Stabilized oral pharmaceutical composition |
-
2002
- 2002-12-24 ES ES200202992A patent/ES2215474B1/es not_active Expired - Fee Related
-
2003
- 2003-12-22 AR ARP030104790A patent/AR054964A1/es unknown
- 2003-12-23 DE DE60333312T patent/DE60333312D1/de not_active Expired - Lifetime
- 2003-12-23 US US10/540,490 patent/US7550497B2/en not_active Expired - Fee Related
- 2003-12-23 EP EP03810846A patent/EP1583767B1/en not_active Expired - Lifetime
- 2003-12-23 MX MXPA05006957A patent/MXPA05006957A/es active IP Right Grant
- 2003-12-23 WO PCT/EP2003/014818 patent/WO2004058778A1/en active Application Filing
- 2003-12-23 AT AT03810846T patent/ATE473231T1/de not_active IP Right Cessation
- 2003-12-23 AU AU2003302287A patent/AU2003302287A1/en not_active Abandoned
- 2003-12-23 CA CA002511596A patent/CA2511596A1/en not_active Abandoned
- 2003-12-23 BR BR0317719-0A patent/BR0317719A/pt not_active IP Right Cessation
- 2003-12-23 JP JP2004563195A patent/JP4406371B2/ja not_active Expired - Fee Related
- 2003-12-23 KR KR1020057012068A patent/KR20050088144A/ko not_active Application Discontinuation
- 2003-12-24 CL CL200302749A patent/CL2003002749A1/es unknown
-
2005
- 2005-06-17 NO NO20052994A patent/NO20052994L/no not_active Application Discontinuation
-
2006
- 2006-03-31 HK HK06104001.3A patent/HK1082508A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR20050088144A (ko) | 2005-09-01 |
CL2003002749A1 (es) | 2005-01-07 |
US20060111326A1 (en) | 2006-05-25 |
ATE473231T1 (de) | 2010-07-15 |
NO20052994L (no) | 2005-07-12 |
CA2511596A1 (en) | 2004-07-15 |
ES2215474A1 (es) | 2004-10-01 |
US7550497B2 (en) | 2009-06-23 |
WO2004058778A1 (en) | 2004-07-15 |
EP1583767B1 (en) | 2010-07-07 |
ES2215474B1 (es) | 2005-12-16 |
JP2006512385A (ja) | 2006-04-13 |
DE60333312D1 (de) | 2010-08-19 |
BR0317719A (pt) | 2005-11-22 |
AU2003302287A1 (en) | 2004-07-22 |
MXPA05006957A (es) | 2005-09-30 |
HK1082508A1 (en) | 2006-06-09 |
JP4406371B2 (ja) | 2010-01-27 |
EP1583767A1 (en) | 2005-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR047538A1 (es) | Piridazinonas como antagonistas de las integrinas alfa4 | |
AR036075A1 (es) | Compuestos derivados de pirimidina,triazina,y,pirazina,su uso, un procedimiento para su preparacion y medicamentos que los comprenden | |
CO5631436A2 (es) | Amidas y acidos derivados del bencimidazol para el tratamiento del dolor y la inflamacion | |
AR054182A1 (es) | Derivados de piperidina y su uso como agentes antiinflamatorios. procesos de obtencion y composiciones farmaceuticas | |
AR059778A1 (es) | Compuestos de pirrolotriazina inhibidores de quinasas p38,composiciones farmaceuticas que los contienen y usos en gran variedad de procesos inflamatorios. | |
AR061739A1 (es) | Nuevos derivados naftalenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
AR046200A1 (es) | Derivados de pirazina y su uso farmaceutico. procesos de preparacion y composiciones farmaceuticas | |
AR069417A1 (es) | Piperidinas heteroaril - sustituidas | |
AR034475A1 (es) | Derivados de androstano antiinflamatorios | |
AR050251A1 (es) | Compuestos heterociclicos con nitrogeno heteroatomico y composicion farmaceutica en base al compuesto | |
CO5700754A2 (es) | Derivados de piperazina y su uso en el tratamiento de enfermedades neurologicas y psiquiatricas | |
AR049116A1 (es) | Derivados de piperazina y usos para controlar pestes. | |
ES2253568T3 (es) | Compuestos heterociclicos para el uso en el tratamiento de los trastornos de las vias urinarias. | |
AR063988A1 (es) | Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
AR044078A1 (es) | Dihidroquinazolinas sustituidas | |
AR056861A1 (es) | Compuestos triciclicos fusionados como inhibidores de la necrosis tumoral. composiciones farmaceuticas y procesos de obtencion | |
AR060812A1 (es) | Moduladores de receptores metabotropicos de glutamato mglur5, composiciones farmaceuticas que los contienen y usos en procesos patofisiologicos y trastornos que afectan el scn | |
AR054964A1 (es) | Un compuesto que comprende derivados de fosforamida, procedimiento para preparar dicho compuesto y sus usos | |
CO5631434A2 (es) | Derivados de piridina-carboxamida y su uso como plaguicidas | |
AR042067A1 (es) | Derivados de anilinopirazol utiles en el tratamiento de la diabetes | |
AR054813A1 (es) | Derivados de pirroloquinolinas y sus usos como inhibidores de proteinas quinasas | |
AR059030A1 (es) | Combinacion de derivados de triazina y estimuladores de la secrecion de insulina | |
AR066604A1 (es) | Derivados de arilamida pirimidona, medicamentos que los contienen y usos terapeuticos para prevenir y/o tratar enfermedades neurodegenerativas fundamentalmente. | |
AR058108A1 (es) | Derivados de furopirimida aciclica sustituidos y su uso | |
ES2036213T3 (es) | Procedimiento para preparar derivados tetrahidroisoquinolin-1-ilicos de acidos carboxilicos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |